{
 "ticker": "ARKG",
 "name": "ARK Genomic Revolution ETF",
 "issuer": "ARK",
 "desk": "themes",
 "url": "https://etfiq.com/funds/arkg",
 "html": "https://etfiq.com/funds/arkg",
 "markdown": "https://etfiq.com/funds/arkg.md",
 "as_of": "2026-09-11",
 "verdict": "ARKG holds 33 stocks, and 96% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "3.9%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "ARKG, already in the S&P 500: 3.9%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "98.5%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "ARKG, active share vs the S&P 500: 98.5%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "59.3%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "ARKG, top ten holdings: 59.3%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+74.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "ARKG, total return, 1 year: +74.0%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$1.8bn",
   "source": "the issuer daily holdings, added up, as of Sep 11, 2026",
   "as_of": "2026-09-11",
   "sentence": "ARKG, net assets: $1.8bn (the issuer daily holdings, added up, as of Sep 11, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.75%",
   "source": "485BPOS XBRL, Nov 26, 2025",
   "as_of": "2026-09-11",
   "sentence": "ARKG, expense ratio: 0.75% (485BPOS XBRL, Nov 26, 2025)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Oct 31, 2014",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "3.9%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "98.5%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "0.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "100.0%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "59.3%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "33",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 11, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "10X GENOMICS INC-CLASS A 10.3%, TWIST BIOSCIENCE CORP 8.3%, TEMPUS AI INC-CL A 7.7%, CRISPR THERAPEUTICS AG 5.9%, PERSONALIS INC 5.9%, ABSCI CORP 4.6%, GUARDANT HEALTH INC 4.4%, NATERA INC 4.3%, CAREDX INC 4.0%, ILLUMINA INC 4.0%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$1.8bn",
   "source": "the issuer daily holdings, added up, as of Sep 11, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u221259.2%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.75%",
   "source": "485BPOS XBRL, Nov 26, 2025"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.76%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "GNOM 40%, WDNA 27%, ARKK 26%, HELX 25%, EKG 24%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+36.1%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+32.8 pts",
   "Gap to Nasdaq-100": "+36.9 pts"
  },
  {
   "window": "6 months",
   "Total return": "+72.8%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+56.8 pts",
   "Gap to Nasdaq-100": "+52.1 pts"
  },
  {
   "window": "1 year",
   "Total return": "+74.0%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+56.5 pts",
   "Gap to Nasdaq-100": "+51.0 pts"
  },
  {
   "window": "3 years",
   "Total return": "+44.5%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u221233.4 pts",
   "Gap to Nasdaq-100": "\u221250.6 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+142.3%",
   "S&P 500": "+361.8%",
   "Gap to S&P 500": "\u2212219.5 pts",
   "Gap to Nasdaq-100": "\u2212529.3 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of ARKG is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 11, 2026, 4% of ARKG by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different."
  },
  {
   "q": "What does ARKG hold?",
   "a": "33 positions as published by its issuer for Sep 11, 2026, with the top ten at 59% of the fund. The largest are 10X GENOMICS INC-CLASS A at 10.3%, TWIST BIOSCIENCE CORP at 8.3%, TEMPUS AI INC-CL A at 7.7%."
  },
  {
   "q": "Has ARKG beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 ARKG returned +74.0% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 56.5 points."
  },
  {
   "q": "What does ARKG cost?",
   "a": "The prospectus expense ratio is 0.75% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.76%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}